Table Graph
   

potential COVID-19 treatments - versus placebo - for COVID 19 outpatients pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.60 [0.30, 1.20]< 18%11 studies (13/-)92.5 %some concernlow moderatecrucial-
deaths 0.75 [0.54, 1.05]< 10%23 studies (25/-)95.5 %lowcritical highcrucial-
deaths (time to event analysis only) 0.80 [0.43, 1.50]< 10%1 study (1/-)75.7 %NAnot evaluable crucial-
hospitalization or death 0.47 [0.34, 0.64]< 171%17 studies (21/-)100.0 %lowcritical highcrucial-
clinical deterioration 0.77 [0.61, 0.98]< 160%8 studies (9/-)98.4 %some concernserious moderateimportant-
clinical improvement 1.08 [0.99, 1.18]> 10%3 studies (3/-)95.7 %lownot evaluable highimportant-
clinical improvement (14-day) 1.13 [0.91, 1.40]> 10%3 studies (3/-)86.6 %some concernnot evaluable moderateimportant-
clinical improvement (21-day) 1.28 [0.79, 2.10]> 10%1 study (1/-)84.1 %NAnot evaluable important-
clinical improvement (28-day) 1.08 [0.98, 1.19]> 10%2 studies (2/-)94.1 %lownot evaluable highimportant-
clinical improvement (7-day) 0.92 [0.51, 1.66]> 10%1 study (1/-)39.1 %NAnot evaluable important-
clinical improvement (time to event analysis only) 1.07 [0.98, 1.17]> 10%2 studies (3/-)93.1 %lownot evaluable highimportant-
hospitalization 0.74 [0.63, 0.88]< 134%20 studies (21/-)100.0 %lowlow highimportant-
mechanical ventilation 0.83 [0.48, 1.41]< 10%4 studies (4/-)75.8 %lownot evaluable highimportant-
Recovery (time to event analysis only) 1.02 [0.92, 1.13]> 10%1 study (2/-)64.7 %NAnot evaluable important-
symptomatic Covid-19 0.56 [0.31, 1.00]< 10%1 study (1/-)97.6 %NAnot evaluable important-
viral clearance 0.93 [0.77, 1.11]> 145%8 studies (9/-)21.4 %some concernnot evaluable moderateimportant-
viral clearance by day 14 0.79 [0.59, 1.07]> 148%3 studies (4/-)6.3 %some concernnot evaluable moderateimportant-
viral clearance by day 7 1.00 [0.76, 1.31]> 143%9 studies (11/-)50.0 %some concernnot evaluable moderateimportant-
emergency room observation for > 6 hours or hospitalization 0.64 [0.47, 0.87]< 10%1 study (1/-)99.8 %NAnot evaluable non important-
ICU admission 0.85 [0.45, 1.61]< 10%2 studies (2/-)69.2 %some concernnot evaluable moderatenon important-
recovery 0.97 [0.87, 1.08]> 10%2 studies (2/-)28.3 %lownot evaluable highnon important-

safety endpoints 00

AE leading to drug discontinuation 0.79 [0.37, 1.69]< 160%4 studies (4/-)72.9 %some concernnot evaluable moderateimportant-
emergent treatment-resistant variants 0.64 [0.08, 4.94]< 167%2 studies (2/-)66.3 %some concernnot evaluable moderateimportant-
related AE (TRAE) 1.74 [1.51, 2.01]< 10%2 studies (2/-)0.0 %lownot evaluable highimportant-
related SAE (TRSAE) 1.01 [0.25, 4.05]< 10%1 study (1/-)49.6 %NAnot evaluable important-
serious adverse events 0.66 [0.49, 0.89]< 120%7 studies (7/-)99.6 %lownot evaluable highimportant-
adverse events 0.85 [0.74, 0.98]< 10%9 studies (9/-)98.7 %lownot evaluable highnon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons